LISATA THERAPEUTICS, INC. (LSTA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
LSTA currently has 9.01M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 8.78% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 11, 2026 |
10-Q filing | 9.0M shares outstanding |
9M | 0 |
| Mar 12, 2026 |
10-K filing | 8.7M shares outstanding |
8.7M | 0 |
| Nov 06, 2025 |
10-Q filing | 8.7M shares outstanding |
8.7M | 0 |
| May 08, 2025 |
10-Q filing | 8.6M shares outstanding |
8.6M | 0 |
| Feb 27, 2025 |
10-K filing | 8.3M shares outstanding |
8.3M | 0 |
| Nov 12, 2024 |
10-Q filing | 8.3M shares outstanding |
8.3M | 0 |
| Aug 12, 2024 |
10-Q filing | 8.3M shares outstanding |
8.3M | 0 |
| May 09, 2024 |
10-Q filing | 8.3M shares outstanding |
8.3M | 0 |
| May 01, 2024 |
S-3 filing: This is an S-3 filing related to the offering of Common Stock, where underwriters may purchase and sell shares in the open market, including short sales, syndicate covering transactions, and stabilizing transactions. |
8.1M | 0 |
| Feb 29, 2024 |
10-K filing | 8.1M shares outstanding |
8.1M | 0 |
| Nov 02, 2023 |
10-Q filing | 8.1M shares outstanding |
8.1M | 0 |
| Aug 14, 2023 |
10-Q filing | 8.0M shares outstanding |
8M | 0 |
| May 09, 2023 |
10-Q filing | 8.0M shares outstanding |
8M | 0 |
| Mar 30, 2023 |
10-K filing | 8.0M shares outstanding |
8M | 0 |
| Nov 10, 2022 |
10-Q filing | 7.9M shares outstanding |
7.9M | 0 |
| Sep 14, 2022 |
Stock Split
8-K filing: Stock split 1-for-15 | Outstanding: 60,533,000 → 7,820,830 |
7.8M | 0 |
| Aug 04, 2022 |
10-Q filing | 60.5M shares outstanding |
61M | 0 |
| May 05, 2022 |
10-Q filing | 60.6M shares outstanding |
61M | 0 |
| Apr 27, 2022 |
8-K filing: Caladrius Biosciences, Inc. entered into a Merger Agreement with Cend Therapeutics, Inc. and a Series D Preferred Stock Purchase Agreement to purchase 1,135,628 shares of Cend's Series D Preferred Stock for approximately $10,000,000. ($10.0M proceeds) |
55M | 0 |
| Mar 22, 2022 |
10-K filing | 55.3M shares outstanding |
55M | 0 |
| Nov 04, 2021 |
10-Q filing | 59.6M shares outstanding |
60M | 0 |
| Aug 05, 2021 |
10-Q filing | 59.5M shares outstanding |
60M | 0 |
| May 06, 2021 |
10-Q filing | 59.5M shares outstanding |
59M | 0 |
| Apr 01, 2021 |
S-3 filing: This is an S-3 filing related to a potential offering of common stock. The underwriters may purchase and sell shares of common stock in the open market, including short sales and stabilizing transactions. |
60M | 0 |
| Feb 25, 2021 |
10-K filing | 59.5M shares outstanding |
60M | 0 |
| Jan 29, 2021 |
S-3 filing: Caladrius Biosciences, Inc. is offering up to 18,750,000 shares of common stock through selling stockholders. |
19M | 16M |
| Nov 05, 2020 |
10-Q filing | 19.4M shares outstanding |
19M | 0 |
| Aug 18, 2020 |
S-3 filing: This S-3 filing registers the resale of common stock and shares issuable upon warrant exercise by selling stockholders, acquired through a private placement, with the company receiving proceeds only if warrants are exercised for cash, intended for working capital and general corporate purposes. |
19M | 0 |
| Aug 13, 2020 |
10-Q filing | 19.3M shares outstanding |
19M | 0 |
| Jun 19, 2020 |
S-1 filing: This S-1 filing relates to the resale of up to 2,123,508 shares of our common stock issuable upon exercise of certain outstanding warrants issued by us in private placement transactions. |
16M | 0 |
| May 07, 2020 |
10-Q filing | 12.8M shares outstanding |
13M | 0 |
| Mar 05, 2020 |
10-K filing | 10.6M shares outstanding |
11M | 0 |